Advertisement

Clinical PET pp 357-371 | Cite as

Melanoma, Myeloma, and Sarcoma

  • E. Edmund Kim
  • Franklin C. L. Wong
Chapter
  • 253 Downloads

Abstract

Cutaneous melanoma is a readily curable tumor, with 85% of diagnosed patients enjoying long-term survival following simple surgical excision. There has been a steady increase in melanoma incidence over the past century. In the United States, melanoma is diagnosed in at least 54,200 people a year, approximately 15 in 100,000.1 Disseminated melanoma is a devastating illness with limited effective treatment options, prompting the evolution of efforts designed to identify metastatic disease early and to develop novel biologic therapies. The application of immunotherapy has so far provided benefit to only a small percentage of patients. In the majority of patients with metastatic disease, many of whom are young, the chemotherapy or biologic therapy is unsuccessful.

Keywords

Single Photon Emission Compute Tomography Soft Tissue Sarcoma Malignant Peripheral Nerve Sheath Tumor Uveal Melanoma Malignant Fibrous Histiocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Scott IU, Murray TG, Randall Hughes J. Evaluation of imaging techniques for detection of extraocular extension of choroidal melanoma. Arch Ophthalmol 1998; 116: 897–901.PubMedGoogle Scholar
  3. 3.
    Modorati G, Brancato R, Paganelli G, et al. Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol 1994; 78: 19–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Haynie GD, Shen TT, Gragoudas ES, et al. Flow cytometric analysis of peripheral blood lymphocytes in patients with choroidal melanoma. Am J Opthalmol 1997; 124: 357–361.Google Scholar
  5. 5.
    Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Hematol 1997; 99: 649–654.CrossRefGoogle Scholar
  6. 6.
    Fletcher J, Kozakewich H, Hoffer F, et al. Diagnostic relevance of clonal chromosome aberrations in malignant soft tissue tumors. N Engl J Med 1991; 324: 436–441.PubMedCrossRefGoogle Scholar
  7. 7.
    Conlon K, Casper E, Brennan M. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995; 2: 26–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Laluaglia M, Heller G, Ghavimi F, et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 1994; 73: 109–114.CrossRefGoogle Scholar
  9. 9.
    Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106–109.PubMedGoogle Scholar
  10. 10.
    Bloem JL, Taminian AHM, Euldenink F, et al. Radiologic staging of primary bone sarcoma: MRI, scintigraphy, angiography and CT correlated with pathologic examination. Radiology 1988; 169: 805–811.PubMedGoogle Scholar
  11. 11.
    Kagan R, Witt T, Bines S, et al. Gallium-67 scanning for malignant melanoma. Cancer 1998; 61: 272–274.CrossRefGoogle Scholar
  12. 12.
    Kaiff V, Hicks RJ, Ware RE, et al. Evaluation of high-risk melanoma: comparison of F-18 FDG PET and high-dose Ga-67 SPECT. Eur J Nucl Med 2002; 29: 506–515.CrossRefGoogle Scholar
  13. 13.
    Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019–1025.PubMedCrossRefGoogle Scholar
  14. 14.
    Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41: 1491–1494.PubMedGoogle Scholar
  15. 15.
    Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintigraphy and PET in staging malignant melanoma. J Nucl Med 1998; 39: 1892 1897.Google Scholar
  16. 16.
    Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma dopa with F-18 FDG and 0–15 water using compartment and noncompartment analysis. J Nucl Med 2001; 42: 248–256.PubMedGoogle Scholar
  17. 17.
    Durie BGM, Waxman AD, D’Agnolo A, et al. Whole-body F-18 FDG-PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–1463.PubMedGoogle Scholar
  18. 18.
    Schwarzbach M, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of F-18 FDG-PET imaging in soft tissue sarcomas. Ann Surg 2000; 231: 380–386.PubMedCrossRefGoogle Scholar
  19. 19.
    Strauss LG. F-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409 1415.Google Scholar
  20. 20.
    Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic F-18 PET-FDG studies in patients with primary and recurrent soft tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42: 713–720.PubMedGoogle Scholar
  21. 21.
    Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG-PET. J Nucl Med 1998; 39: 250–254.PubMedGoogle Scholar
  22. 22.
    Schwarzbach M, Wideke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by PET. J Nucl Med 1998; 39: 250–254.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • E. Edmund Kim
  • Franklin C. L. Wong

There are no affiliations available

Personalised recommendations